Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
KRYSthis companyKrystal Biotech, Inc.	$299.42	34.82×	5.85×	18.34×	33.92×	78.8%	92.6%	41.5%	52.6%	16.8%	13.1%	2.6%	0.01×	-2.48×	0×	9.95×	0.0%	4	40.92	4	A-
ABEOAbeona Therapeutics Inc.	$2.48	3.93×	1.75×	47.95×	2.87×	-76.4%	73.7%	-1536.9%	1223.1%	44.7%	-44.0%	-30.2%	0.16×	-0.68×	-23.92×	6.93×	0.0%	2	-3.55	2	C
MGTXMeiraGTx Holdings plc	$9.34	-5.6×	-110.38×	7.86×	-7.4×	-554.4%	94.0%	-130.2%	-140.3%	1971.4%	-70.9%	-7.8%	-15.31×	-0.25×	-8.69×	0.75×	0.0%	6	4.07	3	B
RCKTRocket Pharmaceuticals, Inc.	$2.45	-1.75×	1.41×	0×	-1.6×	-80.8%	0.0%	0.0%	0.0%	-80.5%	-75.4%	-48.8%	0.09×	0.25×	-120.84×	6.38×	0.0%	1	-0.82	2	C+
RGNXREGENXBIO Inc.	$8.09	-3.83×	7.23×	4.36×	-7.27×	-438.7%	88.1%	-94.6%	-113.8%	-188.7%	-42.1%	-17.0%	2.54×	-1.7×	-3.58×	2.38×	0.0%	2	-3.81	1	D+
SANASana Biotechnology, Inc.	$2.35	-4.24×	6.41×	0×	-4.48×	-101.4%	0.0%	0.0%	0.0%	-151.8%	-54.1%	-14.0%	0.49×	-0.03×	0×	1.89×	0.0%	1	-6.29	1	D+
Peer median	—	-3.83×	1.75×	4.36×	-4.48×	-101.4%	73.7%	-94.6%	0.0%	-80.5%	-54.1%	-17.0%	0.16×	-0.25×	-8.69×	2.38×	0.0%	2	-3.55	2	—